Insulet (NASDAQ: PODD) reported Q4 EPS of $1.15, $0.12 better than the analyst estimate of $1.03. Revenue for the quarter came in at $597.5 million versus the consensus estimate of $582.7 million.

2025 Outlook:

Revenue Guidance (in constant currency):

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are:

Total Omnipod of 17% to 21%

U.S. Omnipod of 16% to 20%
International Omnipod of 22% to 26%

Drug Delivery of (55)% to (45)%

For the quarter ending March 31, 2025, the Company expects revenue growth of 22% to 25%. Revenue growth ranges by product line are:

Total Omnipod of 23% to 26%

U.S. Omnipod of 21% to 24%
International Omnipod of 28% to 31%

Drug Delivery of (10)% to (5)%

For earnings history and earnings-related data on Insulet (PODD) click here.